Literature DB >> 20970593

Incidence and risk factors for nonmelanoma skin cancer after heart transplantation.

B D Molina1, M G C Leiro, L A Pulpón, S Mirabet, J F Yañez, L A Bonet, F G Vilchez, J F Delgado, N Manito, G Rábago, J M Arizón, N Romero, E Roig, T Blasco, D Pascual, L de la Fuente, J Muñiz.   

Abstract

INTRODUCTION: The incidence of skin cancer in heart transplant (HT) patients is higher than in the general population, reversing the proportion of cutaneous squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) with a predominance of the former. The etiologic role of new immunosuppressants is not well known. We sought to ascertain the incidence of SCC and BCC in HT patients and the risk factors for its occurrence. PATIENTS AND METHODS: We report the incidence of all types of post-HT skin cancer, SCC, and BCC among adult HT patients in Spain (4089 subjects) as well as the influence of gender, age at heart transplant, immunosuppression, and sunlight exposure.
RESULTS: The incidence rates of SCC and BCC, per 1000 persons/year, were 8.5 and 5.2, respectively. Males had a higher risk of SCC but not BCC. Induction therapy increased the risk of SCC and BCC. The relative risk of mycophenolate mofetil (MMF) was 0.3 (0.2-0.6; P<.0005) and azathioprine (AZA) 1.8 (1.2-2.7; P<.0032) for SCC, whereas tacrolimus and cyclosporine showed no difference. The relative risk of BCC was not affected by any immunosuppressant.
CONCLUSION: Age at transplantation>45 years, induction therapy use, and high sunshine zone were risk factors for both SCC and BCC. Different immunosuppressive agents have different risks of nonmelanoma skin cancer, as AZA increases the risk of SCC and MMF is a protective factor. The relative risk of BCC was not affected by any immunosuppressor.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20970593     DOI: 10.1016/j.transproceed.2010.08.003

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  8 in total

Review 1.  Basal cell carcinoma-treatments for the commonest skin cancer.

Authors:  Carola Berking; Axel Hauschild; Oliver Kölbl; Gerson Mast; Ralf Gutzmer
Journal:  Dtsch Arztebl Int       Date:  2014-05-30       Impact factor: 5.594

Review 2.  Roles of the immune system in skin cancer.

Authors:  S Rangwala; K Y Tsai
Journal:  Br J Dermatol       Date:  2011-11       Impact factor: 9.302

3.  Immunosuppressive Medications and Squamous Cell Skin Carcinoma: Nested Case-Control Study Within the Skin Cancer after Organ Transplant (SCOT) Cohort.

Authors:  A E Coghill; L G Johnson; D Berg; A J Resler; N Leca; M M Madeleine
Journal:  Am J Transplant       Date:  2016-02       Impact factor: 8.086

4.  Skin Cancer Development in Solid Organ Transplant Recipients in Switzerland (Swiss Transplant Cohort Study).

Authors:  Nadja Angela Stenz; Susanne Stampf; Andreas W Arnold; Antonio Cozzio; Michael Dickenmann; Olivier Gaide; Mirjam Harms; Robert E Hunger; Emmanuel Laffitte; Michael Mühlstädt; Mirjam Nägeli; Günther F L Hofbauer
Journal:  Dermatology       Date:  2020-11-23       Impact factor: 5.366

Review 5.  Drug-induced photosensitivity: culprit drugs, potential mechanisms and clinical consequences.

Authors:  Georg Amun Hofmann; Benedikt Weber
Journal:  J Dtsch Dermatol Ges       Date:  2021-01       Impact factor: 5.584

6.  Risk prediction model for cutaneous squamous cell carcinoma in adult cardiac allograft recipients.

Authors:  Nandini Nair; Zhiyong Hu; Dongping Du; Enrique Gongora
Journal:  World J Transplant       Date:  2021-03-18

7.  Merkel cell carcinoma in immunosuppressed patients.

Authors:  Janice E Ma; Jerry D Brewer
Journal:  Cancers (Basel)       Date:  2014-06-27       Impact factor: 6.639

8.  The frequency of photosensitizing drug dispensings in Austria and Germany: a correlation with their photosensitizing potential based on published literature.

Authors:  G A Hofmann; G Gradl; M Schulz; G Haidinger; A Tanew; B Weber
Journal:  J Eur Acad Dermatol Venereol       Date:  2019-11-26       Impact factor: 6.166

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.